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Abstract
The coagulation cascade is activated during viral infections as part of the host defense system. 
Coagulation proteases activate cells by cleavage of protease-activated receptors (PAR). Recently, 
we reported that activation of PAR-1enhanced interferon (IFN)-β and CXCL10 expression in 
cardiac fibroblasts and in the hearts of mice infected with Coxsackievirus B3. In this study, we 
used the double-stranded RNA mimetic polyinosinic:polycytidylic acid (poly I:C) to induce an 
anti-viral response in macrophages and mice. Activation of PAR-1 enhanced poly I:C induction of 
IFNβ and CXCL10 expression in the murine macrophage cell line RAW264.7, bone-marrow 
derived mouse macrophages (BMM) and mouse splenocytes. Next, poly I:C was used to induce a 
type I IFN innate immune response in the spleen and plasma of wild-type (WT) and PAR-1−/− 
mice. We found that poly I:C treated PAR-1−/− mice and WT mice given the thrombin inhibitor 
dabigatran etexilate exhibited significantly less IFNβ and CXCL10 expression in the spleen and 
plasma compared to WT mice. These studies suggest that thrombin activation of PAR1 contributes 
to the anti-viral response in mice.
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Introduction
Interferons (IFNs) are divided into three groups: type I (IFNα/β), type II (IFNγ) and type III 
(IFNλ). Most cells express type I IFNα/β. In contrast, IFNγ synthesis is restricted to 
activated T cells and natural killer (NK) cells, and acts to promote the transition from the 
innate to the adaptive immune response.[1] Synthesis of IFNs is an essential part of antiviral 
innate immune responses.[1] Indeed, a deficiency of IFNs or IFN-dependent signaling is 
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associated with increased susceptibility to certain virus infections, such as enteroviruses, 
influenza and herpes virus.[1]
Double-stranded (ds) RNA is a potent trigger of the type I IFN response.[1] dsRNA is part 
of the genome of dsRNA viruses and is an intermediate of ssRNA virus replication.[1] 
DsRNA is detected by the transmembrane receptor toll-like receptor (TLR) 3, as well as the 
cytosolic receptors dsRNA-dependent protein kinase, retinoic acid–inducible gene I, and 
melanoma differentiation-associated gene 5.[2,3] The dsRNA mimetic polyinosinic: 
polycytidylic acid (poly I:C) is used experimentally to stimulate TLR3 and induce the 
expression of type I IFNs in vitro and vivo.[1,3–5]
TLR3 is broadly expressed by myeloid and non-myeloid cells.[3,6] Within the spleen high 
levels of TLR3 expression are present in cells of the red pulp as well as marginal zone, while 
lower levels of expression are present in macrophages and dendritic cells (DCs) in the white 
pulp.[6] TLR3-dependent innate immune activation is essential to fight particular virus 
infections, including poliovirus, rhinovirus, herpes simplex virus, encephalomyocarditis 
virus, and Coxsackievirus group B (CVB).[3] In addition, TLR3 enhances the antiviral 
responses of macrophages against other viruses, such as the monkey and human 
immunodeficiency viruses (HIV).[7,8]
Virus infections activate the coagulation system by inducing tissue factor (TF) expression in 
various cell types.[9–11] Interestingly, one study found that poly I:C induced TF expression 
in endothelial cells but not monocytes.[12] Furthermore, administration of poly I:C to mice 
increased systemic activation of coagulation and fibrin deposition in the liver in a TLR3-
dependent manner.[12] Thrombin is the central protease of the coagulation cascade but also 
activates cells by cleavage of protease-activated receptors (PAR), such as PAR-1.[13] This 
receptor is also activated by other proteases, such as matrix metalloproteinases (MMP) 1 and 
13.[4,9,10,14,15] PAR-1 is expressed by a variety of human and murine immune cells, 
including monocytes/macrophages, DC, T cells, and NK cells.[16,17]
The coagulation and immune systems appear to have a common evolutionary origin.[18] 
Moreover, there is crosstalk between the two systems during infections.[9,10,17,18] It has 
been proposed that TLRs and PARs act as a cooperative sensor system to detect pathogens.
[10,19] We demonstrated that PAR-1 activation enhanced poly I:C induced IFNβ and 
CXCL10 expression in murine cardiac fibroblasts, suggesting interaction between PAR-1 
and TLR3.[4] In a CVB3 mouse model, we observed that a deficiency of PAR-1 was 
associated with reduced type I IFN responses leading to increased myocarditis.[4] In 
addition, inhibition of the PAR-1 activating proteases thrombin or MMP13 led to increased 
myocarditis.[4] Bone marrow transplantation experiments further revealed that PAR-1 on 
both non-hematopoietic and hematopoietic cells contributed to PAR-1 mediated protection 
against CVB3 myocarditis.[4] This finding is consistent with the observation that cardiac 
damage and survival of CVB4-infected TLR3-deficient mice can be improved by adaptive 
transfer of wild-type (WT) macrophages.[20]
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In this study, we utilized poly I:C as surrogate for viral activation and PAR-1−/− mice to 
investigated the role of PAR-1 in the induction of an anti-viral innate immune response in 
macrophages and mice.
Material and Methods
Mice
We used WT and PAR-1−/− mice on a C57BL/6J background.[21] All mouse studies were 
performed with the approval of the University of North Carolina at Chapel Hill Institutional 
Animal Care and Use Committee (IACUC).
Isolation and in vitro stimulation of macrophages, DCs and splenocytes
WT and PAR-1−/− mice (4 mice each genotype, 8–12 weeks old) were used to isolate 
splenocytes or generate bone marrow-derived macrophages (BMMs) and dendritic cells 
(BMDCs). Each isolation was repeated once. For splenocyte isolation, spleens were harvest 
and passed through a 70 µm cell strainer to generate a single cell suspension. Red blood cells 
were lysed and the splenocytes washed and re-suspended at a density of 1 × 106 cells per 
well of a 24 well plate in RPMI 1640 with 10% FBS and 1% penicillin/streptomycin. Cells 
were stimulated with 25 µg/mL poly I:C (γ-radiated, Sigma-Aldrich, St. Louis, MO) and/or 
PAR-1 agonist peptide (TFLLR-NH2, 200 µM, Abgent, San Diego, CA) for 2 hours.
BMMs were generated from bone marrow using the L929-conditioned media method as 
described.[22] BMDCs were derived from bone marrow using GM-CSF and IL-4 (30 ng/mL 
each) as described.[23] RAW264.7 cells, a murine macrophage cell line, were maintained as 
described.[24]
For experiments, BMM were plated at a density of 1 × 106 cells per well of a 12 well plate 
the day before stimulation. The next day cell culture media was replaced with 0.5 mL fetal 
bovine serum (FBS)-free media and the cells were stimulated with poly I:C (25 µg/mL) 
and/or PAR-1 agonist peptide (200 µM) for different times. BMDC were seeded in FBS-
containing culture media at a density of 1 × 106 cells in one mL of media the day before 
stimulation. The next day, cells were stimulated without changing the media with poly I:C 
(25 µg/mL) and/or PAR-1 agonist peptide (200 µM) for 8 hours. RAW264.7 cells were 
seeded at a density of 5 × 105 cells per well of a 12 well plate one day prior stimulation. 
Media was replaced with 0.5 mL FBS-free culture media the next day and the cells were 
stimulated with 5 µg/mL poly I:C and/or 150 µM PAR-1 agonist peptide for indicated times.
For measuring IFNβ promoter activity, RAW264.7 cells were stable transfected with the 
pNiFty2-IFB-SEAP plasmid (containing the Ifnb1 promoter) with Zeocin selection 
(Invivogen, San Diego, CA) using Lipofectamine 2000 (Life Technologies, Carlsbad, CA).
[4] Cells were seeded and treated with poly I:C (5 µg/mL) and/or thrombin (5 nM, human α-
thrombin, Enzyme Research Laboratories, South Bend, IN) mentioned above. The next day, 
media was collected, and SEAP (secreted embryonic alkaline phosphatase) activity was 
detected using QUANTI-blue (Invivogen) at 640 nm with a SpectraMax M5 plate reader 
(Molecular Devices, Sunnyvale, CA). [4]
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In vivo stimulation
Male mice (8–12 weeks old) were injected intraperitoneally (i.p.) with 8 mg/kg poly I:C 
(Sigma-Aldrich) diluted in PBS.[25] Blood was collected from the inferior vena cava and 
plasma prepared as previously described.[11,26]
Thrombin inhibition
To inhibit thrombin, mice were fed mice for 7 days with a custom-made chow (AIN-93M, 
Dyets Inc., Bethlehem, PA) with peanut flavoring (2 g/kg chow) with or without dabigatran 
etexilate (10g/kg chow) as described.[4] The level of anticoagulation was measured as 
described.[4]
CVB3 infection model
A standard CVB3 infection model was used.[4,5,27] Briefly, 6–8 weeks old male mice were 
infected with an intraperitoneal injection of CVB3 Nancy Strain (105 plaque forming units 
in 200 µL saline). Tissue and blood was collected and analyzed 4 days after infection.
Real-time PCR
Total RNA from cultured cells or splenic tissue was isolated by using TRIzol method (Life 
Technologies). One microgram of RNA was reverse transcribed into cDNA using the 
iScript™ RT Supermix (Bio-Rad Laboratories, Hercules, CA).[28,29] Real-time PCR 
primer/probes for IFNβ, IFNγ, CXCL10, CCL5, CXCL1, IRF3, IRF7, viperin, Rpl4, 
GAPDH and 18S were purchased from Integrated DNA Technologies (Coralville, IA). 
CVB3 genome levels were quantified as recently described.[4,5] Real-time PCR reactions 
were performed using the SSoFast™ Advanced Universal Supermix in a BioRad cycler 
(Bio-Rad Laboratories). The housekeeping genes Rpl4 or 18S (for splenic tissue) and 
GAPDH (for cells) were used to correct for variations in input RNA and reaction efficiency.
[11]
ELISA
IFNβ (PBL Assay Science, Piscataway, NJ), CXCL10, CCL5 and CXCL1 (Duo-Set, R&D 
Systems, Minneapolis, MN) ELISAs were used to measure levels of IFNβ and CXCL10, 
CCL5 and CXCL1 in plasma and/or cleared cell culture supernatant (500 × g, 10 min, 4°C).
[4]
Statistics
All statistical analyses were performed using GraphPad Prism (version 5.0; GraphPad 
Software Inc., La Jolla, CA). Data are represented as mean ± SEM. For 2-group comparison 
of continuous data, 2-tailed Student’s t test was used. For multiple-group comparison, data 
were analyzed by 1- or 2-way ANOVA and were Bonferroni corrected for repeated measures 
over time. A P value less than 0.05 was considered significant.
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Results
PAR-1 activation enhances poly I:C induction of IFNβ and CXCL10 expression in murine 
macrophages and splenocytes
Macrophages and DCs are known to reside in the spleen and respond to TLR3 stimulation 
by expressing IFNβ and CXCL10.[25,30,31] In addition, depletion of phagocytic splenic 
macrophages and DC of the marginal zone markedly reduced anti-viral responses.[32] We 
analyzed the role of PAR-1 in poly I:C induction of IFNβ and CXCL10 expression in the 
murine macrophage cell line RAW264.7 as well as BMM and BMDC, and splenocytes from 
WT and PAR-1−/− mice.
Poly I:C induction of IFNβ promotor activity as well as IFNβ and CXCL10 mRNA and 
protein expression in RAW264.7 cells was significantly enhanced by PAR-1 activation 
(Figure 1A–D). Next, we analyzed poly I:C induction of IFNβ mRNA expression and 
CXCL10 protein expression in BMM derived from WT and PAR-1−/− mice. Poly I:C alone 
induced IFNβ mRNA expression in both WT and PAR-1−/− BMM and splenocytes, whereas 
the PAR-1 agonist peptide alone had no effect (Figure 1E and G). Importantly, co-
stimulation of cells with poly I:C and the PAR-1 agonist peptide significantly increased 
IFNβ mRNA expression in WT BMM and splenocytes but not in PAR-1−/− BMM and 
splenocytes (Figure 1E and G). In addition, poly I:C stimulation of WT and PAR-1−/− BMM 
induced CXCL10 expression, which was significantly increased in WT BMM but not 
PAR-1−/− BMM co-stimulated with PAR-1 agonist peptide (Figure 1F). We did not detect 
any CXCL10 expression in splenocytes after 2 hours of poly I:C stimulation.
Poly I:C stimulated PAR-1−/− BMM and BMDC expressed lower levels of CXCL10 than 
WT BMM and BMDC (Figure 1F and data not shown). This result is consistent with 
previous studies showing that poly I:C stimulation of cardiac fibroblasts induces the 
expression of MMP13 that activates PAR-1.[4,10] Similar results were observed for 
CXCL10 protein expression (8 hours) with WT and PAR-1−/− BMDC (data not shown).
Recently, we observed increased levels of CXCL1 in lungs of influenza A infected PAR-1−/− 
mice compared to WT mice.[4] In addition, IL-8, the human homolog of murine CXCL1, is 
directly induced after TLR3 stimulation.[33]. Therefore, we analyzed CXCL1 expression 
after poly I:C and/or PAR-1 stimulation in vitro. Poly I:C induced CXCL1 by splenocytes 
and PAR-1 stimulation alone had no effect (Figure 1H). Unexpectedly, WT splenocytes 
exhibited 3-fold lower levels of CXCL1 mRNA after stimulation with poly I:C compared to 
stimulated PAR-1−/− splenocytes (Figure 1H). Furthermore, activation of PAR-1 in WT 
splenocytes but not PAR-1−/− splenocytes significantly reduced poly I:C induction of 
CXCL1 mRNA expression (Figure 1H).
Poly I:C induces an anti-viral response in wild-type mice
Poly I:C injection in mice leads to maximum type I IFN expression between 2 and 4 hours in 
plasma.[25,34] In addition, poly I:C-mediated synthesis of IFNβ is followed by increased 
CXCL10 plasma levels.[34] In our mouse studies, we focused on changes in gene expression 
in the spleen due to the presence of blood and lymphoid elements as well as its role in 
initiating anti-viral responses to blood-borne pathogens.[25] We also measured immune 
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mediators in the plasma. To model virus-like infection of mice, WT mice were injected with 
poly I:C (8 mg/kg) i.p.. Poly I:C increased IFNβ, IFNγ, CXCL10, CCL5, CXCL1, IRF7 and 
viperin mRNA expression in the spleen after injection (Figure 2A–F). Maximal levels of 
these different immune mediators were observed at different times. The different gene 
expression pattern can be divided into an early (IFNβ, CXCL10, CXCL1), intermediate 
(IRF7, viperin) and late (IFNγ). However, we did not observe any changes in the splenic 
IRF3 mRNA expression after poly I:C injection (Figure 2F). Next, we analyzed the time-
dependent changes in protein expression in the spleen. Maximal levels of IFNβ were 
observed 2 hours after administration of poly I:C injection (Figure 3A). Similar kinetics of 
IFNβ expression was observed in the plasma (Figure 4A). IFNβ induces several anti-viral 
response genes, such as CXCL10 and CCL5.[5,33,34] In addition, poly I:C induces IL8 
expression.[33] Poly I:C increased levels of CXCL10, CCL5 and CXCL1 in the spleen 
(Figure 3C,E,G). Maximal levels of IFNβ and CXCL1 were observed at 2 hours whereas 
CXCL10 and CCL5 peaked at later times. Similar results were observed for the expression 
of these anti-viral proteins in the plasma (Figure 4C,E,G).
PAR-1 deficiency is associated with reduced poly I:C induction of ant-viral proteins in the 
spleen and plasma
Recently, we observed that PAR-1 expression on both non-hematopoietic and hematopoietic 
cells contributed to anti-viral responses against the ssRNA virus CVB3 in mice.[4] To 
determine if PAR-1 contributes to innate immune responses to poly I:C in vivo, WT and 
PAR-1−/− mice were injected with poly I:C and the immune response in the spleen and 
plasma was analyzed. A deficiency of PAR-1 was associated with significantly lower levels 
of poly I:C-dependent induction of IFNβ, IFNγ, CXCL10, IRF7 and viperin but not CCL5 
mRNA expression (Figure 2I). In line with our in vitro data, we observed significant higher 
levels of CXCL1 mRNA in PAR-1−/− spleens compared to WT spleens (Figure 2I). In 
addition, PAR-1−/− mice injected with poly I:C had significant less splenic IFNβ protein 
levels compared to WT mice at 2 but not 4 hours (Figure 3B). The level of splenic CXCL10 
protein in PAR-1−/− mice was also significantly lower at 2 and 4 hours after poly I:C 
injection compared to WT mice (Figure 3D). In addition, CCL5 protein levels were lower in 
the spleens of PAR-1−/− mice injected with poly I:C compared to WT mice (Figure 3F). 
Consistent with the changes in splenic CXCL1 mRNA levels, CXCL1 protein levels in the 
spleens of PAR-1−/− mice injected with poly I:C were significant higher compared to WT 
mice at 2 hours (Figure 3H).
Next, we analyzed the effect of PAR-1 deficiency on poly I:C induction of IFNβ, CXCL10, 
CCL5 and CXCL1 in plasma. PAR-1−/− mice had significant lower levels of IFNβ and 
CXCL10 in the plasma 2 hours after poly I:C treatment compared to WT mice (Figure 4B 
and D). CCL5 plasma levels were lower in PAR-1−/− mice compared to WT mice but this 
difference was not statistically significant (Figure 4F). As expected from the splenic data, 
the CXCL1 plasma levels were significantly higher in PAR-1−/− mice compared to WT mice 
2 hours after poly I:C injection (Figure 4H).
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Inhibition of thrombin is associated with reduced poly I:C induction of anti-viral proteins in 
the spleen and plasma
Thrombin is the primary activator of PAR-1 in vivo.[13] Furthermore, poly I:C injection into 
mice was associated with increased activation of coagulation.[12] We observed maximal 
activation of coagulation, as measured by levels of circulating thrombin-antithrombin 
complexes, at 4 hours post poly I:C injection (data not shown) To determine if thrombin 
contributes to anti-viral responses after poly I:C injection, WT mice were fed with the 
thrombin inhibitor dabigatran etexilate (10g/kg chow) prior poly I:C injection. Dabigatran 
etexilate treatment significant reduced IFNγ, CXCL10, CCL5 and viperin but not IFNβ and 
IRF7 mRNA expression in the spleen 4 hours after poly I:C injection in WT mice compared 
to placebo-treated WT mice (Figure 5A). As observed with PAR-1−/− mice, splenic CXCL1 
mRNA expression was significantly increased with dabigatran etexilate compared to placebo 
fed WT mice (Figure 5A). Furthermore, CXCL10 protein levels in the spleen and plasma 
were significant lower with dabigatran etexilate compared to placebo fed WT mice 4 hours 
after poly I:C injection (Figure 5B,C).
PAR-1 deficiency is associated with reduced anti-viral responses in the spleen after CVB3 
infection
TLR3-dependent signaling in macrophages were shown to mediate protection after CVB4 
infection.[20] We found that PAR-1 deficiency was associated with reduced innate immune 
responses in the heart in CVB3 myocarditis.[4] In addition, CVB3 can infect and persist in 
the spleen and macrophages but its replication is highly suppressed.[35–37] WT and 
PAR-1−/− mice were infected with CVB3 and the response in the spleen and plasma 
analyzed. Consistent with our poly I:C data, PAR-1−/− mice expressed significantly lower 
levels of in IFNβ, IRF7 and CCL5 mRNA expression in the spleen compared to WT 4 days 
after CVB3 infection (Figure 6A). CXCL10 and viperin mRNA expression was also reduced 
in infected PAR-1−/− compared to WT mice spleens but did not reach significance. There 
was no differences in IFNγ between the genotypes. Furthermore, splenic CXCL1 mRNA 
was significant increased in PAR-1−/− compared to infected WT mice spleens (Figure 6A). 
CXCL10 protein levels were significant reduced in the spleen but not in the plasma (Figure 
6B,C). As expected from the fact that CVB3 cannot replicate in macrophages, WT and 
PAR-1−/− mice had similar levels of viral genomes (Figure 6D) indicating that the 
differences in the expression of anti-viral genes was not due to different levels of virus.
Inhibition of thrombin is associated with a reduced anti-viral responses in the spleen after 
CVB3 infection
In our recent paper we showed that thrombin inhibition increased CVB3 myocarditis in mice 
due to a decrease in the innate immune response.[4] In this study, we found that thrombin 
inhibition reduced poly I:C induction of anti-viral gene expression in the spleen. To 
determine if thrombin signaling contributes to the anti-viral responses in the spleen in CVB3 
infected mice, we treated WT mice with dabigatran etexilate or placebo and then infected 
them with CVB3 and measured the anti-viral response at 4 days. As expected, thrombin 
inhibition resulted in a significant reduction of the splenic IFNγ, CXCL10, CCL5 and IRF7 
but not viperin mRNA expression (Figure 7A). IFNβ mRNA was reduced but this reduction 
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did not reach significance (Figure 7A). However, we did not observe any differences in the 
CXCL10 levels in the spleen or plasma (Figure 7B,C). CXCL1 expression was increased in 
dabigatran compared to placebo treated mice 4 days after CVB3 infection (Figure 7A). The 
differences in the anti-viral response in the spleen was due to the effect of thrombin on gene 
expression not on virus load since the spleens of infected dabigatran etexilate and placebo 
treated mice showed comparable CVB3 genome levels (Figure 7D).
Discussion
The immune and blood coagulation systems combine to combat infections.[17,18] DsRNA 
or poly I:C activation of TLR3 induces type I IFN innate immune responses, as well as 
induce TF expression and activation of coagulation.[1,3,9,10,12,17] Here, we showed that 
PAR-1 deficiency is associated with a reduction in poly I:C induction of IFNβ and CXCL10 
expression in the spleen and in the plasma. This observation is likely due to reduced TLR3-
mediated responses in immune cells, including splenic macrophages and DCs. Consistent 
with this notion, we found that PAR-1 deficient BMM, BMDCs and splenocytes expressed 
lower levels of IFNβ and CXCL10 expression in vitro when stimulated with poly I:C and 
PAR-1 agonist compared to WT cells. Interestingly, we found that PAR-1 deficiency is 
associated with higher CXCL1 expression after poly I:C challenge. In addition, thrombin 
inhibition of WT mice produced similar results to PAR-1−/− mice suggesting that the 
thrombin-dependent PAR-1 activation is important for effective innate immune responses in 
the spleen. PAR-1−/− mice and WT mice treated with dabigatran etexilate infected with 
CVB3 also showed a reduction in the anti-viral response and increase in CXCL1 compared 
with WT mice. Together, our results indicate the PAR-1 expression and the thrombin-PAR-1 
pathway contributes to innate immune responses to poly I:C and viral infection.
TLR3 is activated by viral dsRNA reaching the endosomal compartment. This can occur 
when cells, such as macrophages and DCs, phagocytose dsRNA released into the 
extracellular space by dying virus-infected cells or when cells internalize viruses by receptor 
mediated endocytosis.[3] Although normally restricted to the endosome, under certain 
conditions TLR3 can be located on the cell surface.[3,4] TLR3 is expressed throughout the 
spleen.[6] In this study, we showed that PAR-1 is required for the maximal poly I:C 
induction of the IFN innate immune pathway in the spleen. The differences in gene 
expression observed in the spleen of PAR-1−/− mice may, in part, explain the decreased 
levels of IFNβ and CXCL10 levels in the plasma of poly I:C treated PAR-1−/− mice. This 
observation supports our recent findings and the proposed model of cooperative signaling 
between TLRs and PARs during infections.[4,5,9,10,19] Cells of the marginal zone of the 
spleen are the first to encounter the content of the blood, and may be the site where poly I:C 
is detected after i.p. injection.[6] Indeed, IFNβ was the major form of IFN produced in the 
red pulp and marginal zone of the spleen after poly I:C stimulation.[25,38] The differences 
in the splenic innate immune responses after poly I:C injection appears to be due to 
cooperative signaling of PAR-1 and TLR3 on immune cells within the spleen since isolated 
splenocytes exhibited a similar response when stimulated with poly I:C and PAR-1 agonist 
ex vivo. Furthermore, it was shown for some virus species that non-fibroblast like cells, such 
as splenic marginal zone macrophages and DCs, are the primary cells that respond with type 
I IFN and IFN-response gene expression after infection.[39] In addition, depletion of 
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phagocytic splenic macrophages and DCs of the marginal zone markedly reduced anti-viral 
responses including IFN-response genes CXCL10 and CCL5.[32] However, we cannot 
exclude the possibility of signaling from other dsRNA receptors, such as melanoma 
differentiation-associated gene 5, which is also dependent on PAR-1 activation in vivo. 
Although, this scenario seems unlikely since we used non-liposome complexed, naked poly 
I:C, and TLR3−/− mice showed a dramatically reduced response to poly I:C (data not 
shown).
Surprisingly, we observed that the CXCL1 expression was negatively regulated by PAR-1 in 
splenocytes and in mice. CXCL1 is the murine homolog of human IL-8. PAR-1 activation 
reduced CXCL1 expression in splenocytes when cells were stimulated with poly I:C, and 
cells from PAR-1−/− mice expression more CXCL1 after poly I:C stimulation. Furthermore, 
PAR-1 deficiency and thrombin inhibition increased CXCL1 expression in the spleen and 
plasma after poly I:C stimulation or CVB3 infection. Interestingly, it was shown that 
increased IRF3 activity was associated with higher IFNβ, CXCL10 and IRF7 but lower 
CXCL1/IL-8 and other proinflammatory cytokine expression levels in microglia and 
astrocytes.[40,41] This was due to protein kinase B (PKB)-dependent inhibition of NFκB. In 
addition, PAR-1 activation was shown to activate PKB.[42] Moreover, IFNβ was shown to 
suppress IL-8 gene expression by modulating NFκB p65 and therefore reduce the binding to 
the κB element within the IL-8 promotor.[43] These findings are in line with our recently 
proposed hypothesis that PAR-1 activation inhibits the NFκB pathway after TLR3 
stimulation.[9]
The TLR3-IFN pathway in immune cells, such as macrophages, was shown to limit viral 
replication of different viruses, such as CVB, influenza, poliovirus, rhinovirus, herpes 
simplex and HIV.[3,7,8,20,31] Furthermore, we and others showed that viral infections lead 
to increased TF expression in the infected tissue and activation of coagulation.[4,9–11,27] In 
addition, poly I:C injection leads to activation of coagulation in mice.[12] More recently, it 
was shown that known PAR-1 activating proteases, such as MMP1 and MMP13, are highly 
expressed in respiratory syncytial virus infected mouse lungs and infected human lung 
epithelial cells in vitro.[44] Here, we showed that thrombin is one of the possible activators 
of PAR-1 after poly I:C injections. Inhibition of thrombin during in vivo poly I:C stimulation 
resulted in reduced IFNβ and IFNβ-response gene expression in the spleen and plasma. 
However, the dabigatran etexilate effect was weaker than the effect observed with a global 
PAR-1 deficiency which suggests that other PAR-1 activators such as MMPs may also be 
involved in the in vivo response to poly I:C. Furthermore, PAR-1 deficiency and thrombin 
inhibition led to reduced IFN responses in the spleen of mice 4 days after CVB3. The 
observed reduction was not due to different virus-dependent thrombin-PAR-1 signaling since 
both infected WT and PAR-1−/− mice as well as infected placebo and dabigatran etexilate-
treated mice showed comparable splenic CVB3 genome levels.
Interestingly, PAR-1 and PAR-2 have the opposite effects on TLR3-dependent induction of 
IFNβ expression.[9,10,45] In contrast to PAR-1 deficient cells, PAR-2 deficient cells exhibit 
increased levels of IFNβ expression in response to poly I:C, and PAR-2−/− mice are 
protected from CVB3 and influenza A/H1N1 infection.[4,5,33] We speculate that the innate 
anti-viral response is stimulated by host proteases, such as thrombin and MMP13, whereas 
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viral proteases may activate PAR-2 in an attempt to dampen the anti-viral response to the 
virus.
With regard to the potential clinical significance of our findings, it is possible that 
interference with the PAR-1 pathway with direct thrombin inhibitors, such as dabigatran 
etexilate, MMP13 inhibitors or direct PAR-1 inhibitors may increase the risk and severity of 
viral infection as we showed in a mouse CVB3 myocarditis model.[4] However, the 
importance of the PAR-1 signaling might be only applicable for an initial viral infection or 
in immunocompromised individuals.
A different scenario may occur with virus infections that persist in the body and lead to 
chronic activation of the innate immune system and clotting system as observed in HIV.
[46,47] For instance, it was shown that even under highly efficient antiretroviral therapy an 
on-going innate immune response and coagulation activation was associated with up to a 30-
fold increase in mortality in HIV patients compared to un-infected controls.[46,48] Despite 
undetectable virus levels, patients under antiretroviral therapy exhibit chronically elevated 
levels of type I IFNs, CXCL10, and coagulation markers, such as plasma TF and D-dimer.
[46–48] In the case of a retroviral infection, anticoagulation and/or PAR-1 inhibition may 
reduce the overall mortality in HIV infected patients by direct affecting the activation of 
coagulation system, as well as dampen the coagulation-dependent immune system 
activation.[47] In line with our proposed mechanism, there are two ongoing clinical studies 
to use targeted anticoagulation therapy with the FXa inhibitor Edoxaban (TACTICAL-HIV, 
NCT02339415) or the PAR-1 inhibitor Vorapaxar (ADVICE, NCT02394730) in patients 
with HIV infection who are successfully treated with combination antiretroviral therapy. 
Both studies will compare the safety and efficacy of either Edoxaban or Vorapaxar in 
reducing markers of cellular immune activation in HIV disease.
In summary, we show that PAR-1 activation contributes to poly I:C induction of TLR3/IFN 
responses in isolated macrophages and splenocytes and mice. Our results highlight the 
important crosstalk between the activation of coagulation and early innate antiviral 
responses in immune cells and the spleen in general.
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Figure 1. Effect of PAR-1 activation and deficiency on poly I:C induction of gene expression in 
macrophages and splenocytes
IFNβ promotor activity (A) measured by SEAP release in the media from pNiFty2-IFB-
SEAP plasmid expressing RAW264.7 macrophages stimulated with poly I:C (5 µg/mL) with 
or without PAR-1 agonist peptide (150 µM) for 24 hours. IFNβ (B) and CXCL10 (C) 
mRNA expression in stimulated RAW264.7 macrophages for 2 hours. Levels of mRNA are 
shown relative to poly I:C-stimulated cells which were set to 1. (D) Levels of CXCL10 in 
the cell culture media of RAW264.7 macrophages with or without poly I:C (5 µg/mL) with 
or without PAR-1 agonist peptide (150 µM) for 7 hours. (E) IFNβ mRNA expression in WT 
Antoniak et al. Page 14
J Innate Immun. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(white bars) and PAR-1−/− (black bars) BMM before and after stimulation with poly I:C (25 
µg/mL) with or without PAR-1 agonist peptide (200 µM) for 2 hours. Results are shown 
relative to poly I:C-stimulated WT splenocytes or BMM which were set to 1. (F) Levels of 
CXCL10 in the cell culture media of WT (white bars) and PAR-1−/− (black bars) BMM 
before and after stimulation with or without poly I:C (25 µg/mL) with or without PAR-1 
agonist peptide (200 µM) for 8 hours. (G) IFNβ and CXCL1 (H) mRNA expression in WT 
(white bars) and PAR-1−/− (black bars) splenocytes before and after stimulation with poly 
I:C (25 µg/mL) with or without PAR-1 agonist peptide (200 µM) for 2 hours. Results are 
shown relative to poly I:C-stimulated WT splenocytes or BMM which were set to 1. Data 
were normalized to GAPDH mRNA levels. Data (mean ± SEM; n > 4) presented as AU 
(arbitrary units) if not stated otherwise were analyzed by 1-way (A–D) and 2-way ANOVA 
(E–H). Statistical significance is shown as *P<0.05, # P<0.05 vs. unstimulated control 
within the same genotype or unstimulated control and $ P<0.05 vs. poly I:C alone.
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Figure 2. PAR-1 deficiency leads to altered splenic mRNA expression of innate immune response 
genes after poly I:C injection
Wild-type (WT) mice were injected with poly I:C (8 mg/kg) and levels of IFNβ (A), IFNγ 
(B), CXCL10 (C), CCL5 (D), CXCL1 (E), IRF3 (F), IRF7 (G) and viperin (H) mRNA 
expression were quantified by real-time PCR before, 2, 4 and 6 hours after injection. 
Expression levels of controls at 0 hours were set to 1. (I) mRNA expression in spleens of 
WT (white bars) and PAR-1−/− (black bars) mice 2 hours after poly IC injection. Expression 
levels of WT were set to 1. Data were normalized to Rpl4 mRNA levels. Data (mean ± 
SEM; n > 4) presented as AU (arbitrary units) if not stated otherwise were analyzed by 
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analyzed by 1-way ANOVA (A–H) or Student’s t test (I). Statistical significance is shown as 
# P<0.05 vs. unstimulated control and *P<0.05 vs WT.
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Figure 3. PAR-1 deficiency leads to altered splenic protein expression of innate immune response 
genes after poly I:C injection
Changes in splenic protein levels of IFNβ (A), CXCL10 (C), CCL5 (E) and CXCL1 (G) in 
wild-type (WT, white bars) mice before, 2, 4 and 6 hours after poly I:C injection (8mg/kg). 
IFNβ (B), CXCL10 (D), CCL5 (F) and CXCL1 (H) protein levels in spleens of WT (white 
bars) and PAR-1−/− (black bars) mice 2 and 4 hours after poly I:C injection. Data (mean ± 
SEM; n > 4) were analyzed by 1-way (A,C,E,G) and 2-way ANOVA (B,D,F,H). Statistical 
significances is shown as * P<0.05 and # P<0.05 vs. 0 hours.
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Figure 4. PAR-1 deficiency leads to altered plasma protein expression after poly I:C injection
Changes in plasma protein levels of IFNβ (A), CXCL10 (C), CCL5 (E) and CXCL1 (G) in 
wild-type (WT, white bars) mice before, 2, 4 and 6 hours after poly I:C injection (8mg/kg). 
IFNβ (B), CXCL10 (D), CCL5 (F) and CXCL1 (H) protein levels in plasma of WT (white 
bars) and PAR-1−/− (black bars) mice 2 and 4 hours after poly I:C injection. Data (mean ± 
SEM; n >5) were analyzed by 1-way (A,C,E,G) and 2-way ANOVA (B,D,F,H). Statistical 
significances is shown as * P<0.05 and # P<0.05 vs. 0 hours.
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Figure 5. Thrombin inhibition alters the immune response in the spleen and plasma to poly I:C
WT mice were treated with dabigatran etexilate (10g/kg chow, black hatched bars) or 
placebo (white bars) for 7 days prior poly I:C challenge (8mg/kg). (A) mRNA expression in 
the spleen 4 hours after poly IC injection. Data were normalized to Rpl4 mRNA levels. 
CXCL10 levels in the spleen (B) and plasma (C) 4 hours after poly I:C injection. Data 
(mean ± SEM; n >5) presented as AU (arbitrary units) if not stated otherwise were analyzed 
by Student’s t test. Statistical significances is shown as * P<0.05
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Figure 6. PAR-1 deficiency is associated with altered immune responses in the spleen of CVB3 
infected mice
WT (white bars) and PAR-1−/− (black bars) were infected with CVB3. (A) mRNA 
expression in the spleen 4 days after CVB3 infection. CXCL10 levels in the spleen (B) and 
plasma (C) 4 days after CVB3 infection. (D) CVB3 genome levels in the spleen. Data were 
normalized to Rpl4 mRNA (A) or 18S (D) levels. Data (mean ± SEM; n >5) presented as 
AU (arbitrary units) if not stated otherwise were analyzed by Student’s t test. Statistical 
significances is shown as * P<0.05
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Figure 7. Thrombin inhibition is associated with altered immune responses in the spleen of 
CVB3 infected mice
WT mice were treated with dabigatran etexilate (10g/kg chow, gray bars) or placebo (white 
bars) for 7 days prior CVB3 infection. (A) Levels of mRNA expression in the spleen 4 days 
after CVB3 infection. CXCL10 levels in the spleen (B) and plasma (C) 4 days after CVB3 
infection. (D) CVB3 genome levels in the spleen. Data were normalized to Rpl4 mRNA (A) 
or 18S (D) levels. Data (mean ± SEM; n >5) presented as AU (arbitrary units) if not stated 
otherwise were analyzed by Student’s t test. Statistical significances is shown as * P<0.05
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